Gossamer Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GOSS Nasdaq 2836 www.gossamerbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gossamer Bio, Inc.

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 8th, 2026 3:30 pm
Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data - Dec 21st, 2025 5:31 am
Oppenheimer Confident in Positive PROSERA Trial Readout in February 2026 for Gossamer Bio (GOSS) - Dec 15th, 2025 9:11 pm
Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug - Dec 11th, 2025 4:41 pm
How Recent Developments Are Shaping the Gossamer Bio Investment Story - Nov 28th, 2025 6:05 pm
Gossamer Bio to Participate in Upcoming Investor Conferences - Nov 24th, 2025 2:01 pm
Why Analysts Say Gossamer Bio’s Story Is Changing Ahead of Critical Clinical Milestones - Nov 14th, 2025 4:12 am
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates - Nov 5th, 2025 3:35 pm
Gossamer Bio: Q3 Earnings Snapshot - Nov 5th, 2025 2:29 pm
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update - Nov 5th, 2025 2:01 pm
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream - Oct 22nd, 2025 5:00 am
Sector Update: Health Care Stocks Decline Premarket Thursday - Sep 25th, 2025 7:15 am
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - Sep 25th, 2025 5:41 am
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension - Sep 25th, 2025 5:31 am
Gossamer Bio, Inc. (GOSS) Stock Jumps 18% on FDA Updates and Seralutinib Progress - Sep 23rd, 2025 5:22 pm
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Sep 22nd, 2025 5:31 am
Gossamer Bio (GOSS): Assessing Valuation After Encouraging Phase 2 Data and Analyst Optimism - Sep 15th, 2025 5:00 am
Gossamer Bio (GOSS) Is Up 17.7% After Seralutinib Gains Key FDA Support and Clinical Progress - Sep 13th, 2025 7:03 am
H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects - Sep 11th, 2025 11:15 am
Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case - Sep 11th, 2025 1:31 am